OKYO Pharma Limited (OKYO)
NASDAQ: OKYO · Real-Time Price · USD
2.670
-0.293 (-9.89%)
Aug 13, 2025, 4:00 PM - Market closed
Company Description
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom.
Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis.
The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
OKYO Pharma Limited
| Country | United Kingdom |
| Founded | 2007 |
| IPO Date | May 17, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Gary Jacob |
Contact Details
Address: 14/15 Conduit St, Floor 4 London, W1S 2XJ United Kingdom | |
| Phone | 44 20 7495 2379 |
| Website | okyopharma.com |
Stock Details
| Ticker Symbol | OKYO |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| IPO Price | $4.00 |
| CIK Code | 0001849296 |
| CUSIP Number | 679345108 |
| ISIN Number | US6793451088 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Gary S. Jacob Ph.D. | Chief Executive Officer and Executive Director |
| Michael Paul Beck | Founder |
| Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2025 | 20-F/A | Filing |
| Aug 5, 2025 | SCHEDULE 13G/A | Filing |
| Jul 18, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Jul 17, 2025 | 6-K | Report of foreign issuer |
| Jul 16, 2025 | 6-K | Report of foreign issuer |
| Jun 11, 2025 | 6-K | Report of foreign issuer |
| Jun 11, 2025 | 424B5 | Filing |
| May 27, 2025 | SCHEDULE 13G | Filing |
| May 19, 2025 | 6-K | Report of foreign issuer |
| May 1, 2025 | 6-K | Report of foreign issuer |